Published in J Immunol on July 15, 2003
Translating costimulation blockade to the clinic: lessons learned from three pathways. Immunol Rev (2009) 1.66
Anti-CD40 monoclonal antibody synergizes with CTLA4-Ig in promoting long-term graft survival in murine models of transplantation. J Immunol (2009) 1.21
CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Invest (2013) 1.04
Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer. Cancer Cell (2011) 1.02
Fas expression by tumor stroma is required for cancer eradication. Proc Natl Acad Sci U S A (2013) 0.95
Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. Hepatology (2012) 0.93
Viral sequestration of antigen subverts cross presentation to CD8(+) T cells. PLoS Pathog (2009) 0.93
A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells. Retrovirology (2011) 0.92
Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. Immunity (2016) 0.89
Targeting lymphotoxin-mediated negative selection to prevent prostate cancer in mice with genetic predisposition. Proc Natl Acad Sci U S A (2009) 0.86
CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors. J Immunol (2008) 0.86
RNAi-mediated TCR knockdown prevents autoimmunity in mice caused by mixed TCR dimers following TCR gene transfer. Mol Ther (2014) 0.83
Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells. J Immunol (2012) 0.83
Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic Tumors. Clin Cancer Res (2015) 0.82
CD8(+)NKT-like cells regulate the immune response by killing antigen-bearing DCs. Sci Rep (2015) 0.81
CD8 T cells recruited early in mouse polyomavirus infection undergo exhaustion. J Immunol (2012) 0.81
Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors. Cancer Immunol Immunother (2007) 0.79
Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones. Virology (2007) 0.78
Direct presentation regulates the magnitude of the CD8+ T cell response to cell-associated antigen through prolonged T cell proliferation. J Immunol (2010) 0.78
Preventing tumor escape by targeting a post-proteasomal trimming independent epitope. J Exp Med (2016) 0.78
Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model. J Hepatol (2016) 0.77
Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors. Cancer Immunol Immunother (2014) 0.76
Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature (2017) 0.76
Type I Interferons Regulate the Magnitude and Functionality of Mouse Polyomavirus-Specific CD8 T Cells in a Virus Strain-Dependent Manner. J Virol (2016) 0.75
Characterization of a Broadly Reactive Anti-CD40 Agonistic Monoclonal Antibody for Potential Use as an Adjuvant. PLoS One (2017) 0.75
Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103(+) dendritic cells in late-stage ovarian cancer. Oncoimmunology (2016) 0.75
Tumour ischaemia by interferon-γ resembles physiological blood vessel regression. Nature (2017) 0.75
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature (2003) 10.16
CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature (2005) 3.81
Dynamic programming of CD8+ T lymphocyte responses. Nat Immunol (2003) 3.73
Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation. Nat Immunol (2010) 3.48
The design and implementation of the immune epitope database and analysis resource. Immunogenetics (2005) 3.00
The generation of protective memory-like CD8+ T cells during homeostatic proliferation requires CD4+ T cells. Nat Immunol (2006) 2.96
A critical role for Stat3 signaling in immune tolerance. Immunity (2003) 2.41
A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol (2003) 2.04
Autocrine IL-2 is required for secondary population expansion of CD8(+) memory T cells. Nat Immunol (2011) 1.98
Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr (2014) 1.96
IL-7 regulates basal homeostatic proliferation of antiviral CD4+T cell memory. Proc Natl Acad Sci U S A (2004) 1.79
Efficient T cell activation via a Toll-Interleukin 1 Receptor-independent pathway. Immunity (2006) 1.78
Plasticity in programming of effector and memory CD8 T-cell formation. Immunol Rev (2010) 1.59
Sphingosine kinase 1 protein and mRNA are overexpressed in non-Hodgkin lymphomas and are attractive targets for novel pharmacological interventions. Leuk Lymphoma (2008) 1.57
Cutting edge: murine cytomegalovirus induces a polyfunctional CD4 T cell response. J Immunol (2008) 1.50
Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med (2002) 1.48
CD40L blockade prevents autoimmune diabetes by induction of bitypic NK/DC regulatory cells. Immunity (2002) 1.48
Immune defects in 28-kDa proteasome activator gamma-deficient mice. J Immunol (2004) 1.46
Another view of T cell antigen recognition: cooperative engagement of glycolipid antigens by Va14Ja18 natural T(iNKT) cell receptor [corrected]. J Immunol (2003) 1.38
Lck dephosphorylation at Tyr-394 and inhibition of T cell antigen receptor signaling by Yersinia phosphatase YopH. J Biol Chem (2003) 1.34
Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells. J Exp Med (2011) 1.30
Cytosolic entry controls CD8+-T-cell potency during bacterial infection. Infect Immun (2006) 1.29
Dlgh1 coordinates actin polymerization, synaptic T cell receptor and lipid raft aggregation, and effector function in T cells. J Exp Med (2005) 1.25
The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in mice. J Clin Invest (2010) 1.24
Protein kinase C-theta is an early survival factor required for differentiation of effector CD8+ T cells. J Immunol (2005) 1.17
Tyrosine phosphorylation of VHR phosphatase by ZAP-70. Nat Immunol (2002) 1.16
Mucosal memory CD8⁺ T cells are selected in the periphery by an MHC class I molecule. Nat Immunol (2011) 1.15
An HLA-A2.1-transgenic rabbit model to study immunity to papillomavirus infection. J Immunol (2006) 1.09
TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J Immunol (2008) 1.08
Preferential use of B7.2 and not B7.1 in priming of vaccinia virus-specific CD8 T cells. J Immunol (2009) 1.05
The CD4⁺ T-cell help signal is transmitted from APC to CD8⁺ T-cells via CD27-CD70 interactions. Nat Commun (2012) 1.04
New associations of human papillomavirus, Simian virus 40, and Epstein-Barr virus with human cancer. J Natl Cancer Inst (2002) 1.03
Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells. Cancer Res (2011) 1.03
Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells. Nat Med (2003) 1.00
Probing the 'labyrinth' linking the innate and adaptive immune systems. Nat Immunol (2007) 0.99
Protective and pathological roles of virus-specific and bystander CD8+ T cells in herpetic stromal keratitis. J Immunol (2004) 0.99
The dual role of CD8+ T lymphocytes in the development of stress-induced herpes simplex encephalitis. J Neuroimmunol (2003) 0.98
Removal of C-terminal SRC kinase from the immune synapse by a new binding protein. Mol Cell Biol (2005) 0.97
Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope. J Immunol (2005) 0.94
Herpetic stromal keratitis in the absence of viral antigen recognition. Cell Immunol (2002) 0.94
Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. Hepatology (2012) 0.93
Cutting edge: a crucial role for B7-CD28 in transmitting T help from APC to CTL. J Immunol (2002) 0.91
Polyfunctional CD4+ T cell responses to immunodominant epitopes correlate with disease activity of virulent Salmonella. PLoS One (2012) 0.91
Differential B7-CD28 costimulatory requirements for stable and inflationary mouse cytomegalovirus-specific memory CD8 T cell populations. J Immunol (2011) 0.90
The TRAIL of helpless CD8+ T cells in HIV infection. AIDS Res Hum Retroviruses (2008) 0.89
B7-mediated costimulation of CD4 T cells constrains cytomegalovirus persistence. J Virol (2010) 0.89
Invariant NKT cells induce plasmacytoid dendritic cell (DC) cross-talk with conventional DCs for efficient memory CD8+ T cell induction. J Immunol (2013) 0.88
Lipid raft targeting of hematopoietic protein tyrosine phosphatase by protein kinase C theta-mediated phosphorylation. Mol Cell Biol (2006) 0.88
Anti-CD40 conditioning enhances the T(CD8) response to a highly tolerogenic epitope and subsequent immunotherapy of simian virus 40 T antigen-induced pancreatic tumors. J Immunol (2007) 0.88
Presentation of human T cell leukemia virus type 1 (HTLV-1) Tax protein by dendritic cells: the underlying mechanism of HTLV-1-associated neuroinflammatory disease. J Leukoc Biol (2009) 0.87
Paradoxical effect of reduced costimulation in T cell-mediated colitis. J Immunol (2007) 0.86
CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors. J Immunol (2008) 0.86
Duration of CTL activation regulates IL-2 production required for autonomous clonal expansion. Eur J Immunol (2006) 0.85
CD154 is a negative regulator of autoaggressive CD8+ T cells in type 1 diabetes. Proc Natl Acad Sci U S A (2004) 0.85
Nab2 regulates secondary CD8+ T-cell responses through control of TRAIL expression. Blood (2011) 0.84
SLAT regulates CD8+ T cell clonal expansion in a Cdc42- and NFAT1-dependent manner. J Immunol (2012) 0.84
Accumulation of CD8+ T cells in advanced-stage tumors and delay of disease progression following secondary immunization against an immunorecessive epitope. J Immunol (2006) 0.83
Why Do CD8+ T Cells become Indifferent to Tumors: A Dynamic Modeling Approach. Front Physiol (2011) 0.83
Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells. J Immunol (2012) 0.83
IL-2 gets with the program. Nat Immunol (2006) 0.83
Rescue of memory CD8+ T cell reactivity in peptide/TLR9 ligand immunization by codelivery of cytokines or CD40 ligation. Virology (2005) 0.82
Interleukin-2 rescues helpless effector CD8+ T cells by diminishing the susceptibility to TRAIL mediated death. Immunol Lett (2011) 0.82
Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. Cancer Biol Ther (2015) 0.82
Enhancement of proliferation and downregulation of TRAIL expression on CD8+ T cells by IL-21. Eur J Immunol (2010) 0.81
CD8 T cells recruited early in mouse polyomavirus infection undergo exhaustion. J Immunol (2012) 0.81
Distinct roles of cytolytic effector molecules for antigen-restricted killing by CTL in vivo. Immunol Cell Biol (2010) 0.81
An SV40 VP1-derived epitope recognized by CD8+ T cells is naturally processed and presented by HLA-A*0201 and cross-reactive with human polyomavirus determinants. Virology (2008) 0.81
T cell exhaustion: a means or an end? Nat Immunol (2013) 0.81
TRAIL-expressing CD8+ T cells mediate tolerance following soluble peptide-induced peripheral T cell deletion. J Leukoc Biol (2010) 0.81
The assembly of functional beta(2)-microglobulin-free MHC class I molecules that interact with peptides and CD8(+) T lymphocytes. Int Immunol (2002) 0.80
BLT for speed. Nat Immunol (2003) 0.80
T cell memory. Semin Immunol (2009) 0.80
A structural rationale for SV40 Vp1 temperature-sensitive mutants and their complementation. Protein Sci (2006) 0.79
Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma. Cancer Biol Ther (2010) 0.79
Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors. Cancer Immunol Immunother (2007) 0.79
CD40 signaling and autoimmunity. Curr Dir Autoimmun (2002) 0.78
Combined anti-CD40 conditioning and well-timed immunization prolongs CD8+ T cell accumulation and control of established brain tumors. J Immunother (2008) 0.78
Using HLA-A2.1 Transgenic Rabbit Model to Screen and Characterize New HLA-A2.1 Restricted Epitope DNA Vaccines. J Vaccines Vaccin (2010) 0.78
Direct presentation regulates the magnitude of the CD8+ T cell response to cell-associated antigen through prolonged T cell proliferation. J Immunol (2010) 0.78
Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones. Virology (2007) 0.78
Immunology. Ex uno plura. Science (2009) 0.78
T cells control the generation of nanomolar-affinity anti-glycan antibodies. J Clin Invest (2017) 0.78